The Stock Network Interview – Making the business case for MagSense® cancer imaging
Izaac Ronay from The Stock Network sat down with Imagion Biosystems’ Ward Detwiler to discuss the new written series, “10 Things to Know About MagSense®”, which
Izaac Ronay from The Stock Network sat down with Imagion Biosystems’ Ward Detwiler to discuss the new written series, “10 Things to Know About MagSense®”, which
Bringing molecular specificity to MRI could change the way cancer is diagnosed. We’re proud of the first-of-its-kind technology behind MagSense®, but breakthrough technology alone does
Lel Smits from The Stock Network sat down with Imagion Biosystems’ Bob Proulx to discuss how MagSense® looks to improve upon today’s imaging, what the
Separating lethal disease from indolent disease remains the persistent difficulty, and molecular MRI may offer a way to see the difference. Prostate cancer is the
Lel Smits from The Stock Network sat down with Imagion Biosystems’ Bob Proulx to discuss how the company is moving through the critical steps required
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)
We’re on a mission to make cancer more detectable.
